Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers

Journal of Supportive Oncology

Volumn 5, Issue 4 SUPPL. 2, 2007, Pages 68-69

  Desjardins, Robert E ^a   Tempel, Donna L ^a   Lucek, Rudolph ^a   Kuter, David J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AKR 501; HORMONE RECEPTOR STIMULATING AGENT; PLACEBO; THROMBOPOIETIN RECEPTOR AGONIST; UNCLASSIFIED DRUG; YM 477;

AREA UNDER THE CURVE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG SAFETY; HUMAN; MEGAKARYOCYTE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOLUNTEER;

EID: 34250618306     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (1)

1. Desjardins RE, Tempel DL, Lucek R, Kuter DJ. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9-12, 2006; Orlando, Florida. Abstract 477.